This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Chugai Pharmaceutical Identifier:
First received: May 6, 2003
Last updated: May 13, 2013
Last verified: May 2013

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than zoledronate in treating women who have breast cancer and bone metastases.

PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with that of zoledronate in treating women who have breast cancer and bone metastases.

Condition Intervention Phase
Breast Cancer Hypercalcemia of Malignancy Metastatic Cancer Pain Biological: monoclonal antibody CAL Drug: zoledronic acid Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: A Phase I-II, 24-Week, Multi-Center, Double-Blind, Randomized, Dose-Ranging Study To Evaluate The Safety And Efficacy Of A Humanized Monoclonal Antibody To PTHrP Versus Zoledronic Acid In Patients With Breast Cancer Metastatic To Bone

Resource links provided by NLM:

Further study details as provided by Chugai Pharmaceutical:

Study Start Date: November 2002
Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Compare the safety and tolerability of monoclonal antibody CAL vs zoledronate in women with breast cancer and bone metastases.
  • Compare, preliminarily, the potential effects of these drugs on skeletal events/manifestations related to bone metastases, including hypercalcemia, bone pain, bone metastatic lesions, complications (e.g., pathologic fracture and spinal cord compression), and interventions (e.g., surgery and radiotherapy) in these patients.
  • Compare changes in ECOG performance status in patients treated with these drugs.
  • Determine the pharmacokinetics of monoclonal antibody CAL in these patients.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to average prestudy pain score on question 3 of a daily electronic telephone pain diary (less than 3 vs 3 or more) and prior bisphosphonate therapy (yes vs no). Patients are randomized to 1 of 4 treatment arms.

  • Arm I: Patients receive monoclonal antibody CAL IV over 30-60 minutes on day 1.
  • Arm II: Patients receive a lower dose of monoclonal antibody CAL as in arm I.
  • Arm III: Patients receive a lower dose (lower than arm II) of monoclonal antibody CAL as in arm I.
  • Arm IV: Patients receive zoledronate IV over 30-60 minutes on day 1. Treatment in all arms repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients keep a pain diary throughout study participation.

Patients are followed at 24 weeks.

PROJECTED ACCRUAL: A total of 72 patients (18 per treatment arm) will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed breast cancer
  • Radiographical evidence of at least 1 bone metastasis

    • No prior radiotherapy or surgery to bone metastasis
    • No radiotherapy or surgery anticipated for bone metastasis within the next 24 weeks
  • Bone pain severity score of at least 1 on 5 of 7 days as determined by question 3 of the Brief Pain Inventory (BPI)
  • No bone metastases to a weight-bearing bone at imminent risk for pathologic fracture or surgical intervention
  • No vertebral metastases that place the patient at imminent risk of spinal cord compression
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status

  • Pre- or post-menopausal

Performance status

  • ECOG 0-2

Life expectancy

  • At least 6 months


  • WBC at least 2,000/mm^3
  • Lymphocyte count at least 500/mm^3
  • Granulocyte count at least 1,000/mm^3
  • Platelet count at least 50,000/mm^3


  • ALT or AST no greater than 2.5 times upper limit of normal (ULN)
  • Bilirubin no greater than 1.5 times ULN


  • Calcium no greater than 10.1 mg/dL
  • No oliguria, defined as less than 30 mL urine per 2-hour collection
  • No acute renal failure
  • Creatinine no greater than 2.5 mg/dL


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • No sepsis
  • No known or anticipated contraindication to study drugs


Biologic therapy

  • Not specified


  • More than 3 weeks since initiation of a new chemotherapy regimen

Endocrine therapy

  • More than 3 weeks since initiation of a new hormonal therapy regimen


  • See Disease Characteristics
  • More than 3 weeks since prior radiotherapy


  • See Disease Characteristics


  • More than 60 days since prior bisphosphonates
  • More than 30 days since prior investigational drugs
  • No change in analgesic drug regimen during the screening period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00060138

United States, Ohio
Ireland Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Chugai Pharmaceutical
National Cancer Institute (NCI)
Study Chair: Paula Silverman, MD Case Comprehensive Cancer Center
  More Information Identifier: NCT00060138     History of Changes
Other Study ID Numbers: CWRU-080235
CDR0000299530 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: May 6, 2003
Last Updated: May 13, 2013

Keywords provided by Chugai Pharmaceutical:
hypercalcemia of malignancy
stage IV breast cancer
recurrent breast cancer
bone metastases

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Paraneoplastic Syndromes
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Calcium Metabolism Disorders
Metabolic Diseases
Water-Electrolyte Imbalance
Antibodies, Monoclonal
Zoledronic acid
Immunologic Factors
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on June 23, 2017